Anthony G. Creber Retired Partner

Speaks:  English, French

Year of Call: 1981 - Ontario

Primary office:  Ottawa

Anthony G. Creber

Tony Creber is a retired partner based in Ottawa. He served as a past leader of Gowling WLG Canada's Intellectual Property Litigation & Strategy Group.

Tony has over 40 years of experience as an IP litigator and was recognized as one of the leading IP litigators in Canada. Tony's practice focused on chemical and pharmaceutical patent litigation, including major patent infringement cases. His practice also included trademark litigation, regulatory issues and advising on strategic IP life cycle matters. He appeared extensively in the Federal Court (both Trial and Appeal) and the Supreme Court of Canada on patent matters, including questions of patentability of life forms, patent licensing and the infringement of biotech patents.

His Supreme Court appearances included leading cases that have defined key aspects of Canadian patent law such as Monsanto v. Schmeiser and Apotex v. Sanofi-Synthelabo ("Plavix").

Tony acted as counsel for patentees and represented many major pharmaceutical companies, including Eli Lilly, BMS, Novartis, Hoffmann-La Roche, Purdue, Allergan and Sanofi.

Throughout his career, Tony was consistently recognized as one of the most pre-eminent IP law practitioners and litigators in Canada by numerous publications. As the lead partner in the Apotex v. Sanofi-Synthelabo Canada case, Tony won the coveted "Milestone Case of the Year 2014" and "Patent Case of the Year 2009" awards given by Managing Intellectual Property. Tony also received Managing Intellectual Property's "IP Practitioner of the Year 2014" award. MIP has ranked him both as a patent and a trademark "star" and he received a gold tier standing for patent litigation in IAM Patent 1000 who called him "legendary." Chambers & Partners has described Tony as "one of the fathers of pharma litigation in Canada." Who's Who Legal named him a "Global Elite Thought Leader" and the Canadian domestic publication Lexpert consistently ranked him as a leading practitioner in IP Litigation in Canada.

Career & Recognition

The go-to person for patent litigation matters in the pharmaceutical and chemical sectors.
- Chambers Global 2014
  • Rankings & Awards
    May 2017
    Canadian Legal Lexpert Directory 2017
  • Qualifications (Year of Call/Admission, etc.)
View Full Career & Recognition Timeline

Career & Recognition

Filter timeline:

Representative Work

Tony has litigated hundreds of patent-related cases, many of which involve multiple patents, multiple defendants and multiple court files. These cases include matters related to the following drugs:

  • Aclasta®
  • Adderall®
  • Alertec®
  • Alimta®
  • Altace®
  • Avalide®
  • Avapro®
  • Axid®
  • Boniva®
  • Capoten®
  • Ceclor®
  • Cellcept®
  • Claritin®
  • Diflun®
  • Dobutrex®
  • Effexor®
  • Evista®
  • Exelon®
  • Exjade®
  • Floxin®
  • Gleevec®
  • Hismanal®
  • Kefzol®
  • Lamisil®
  • Levaquin®
  • Maxipime®
  • Monopril®
  • Motilium®
  • Myfortic®
  • Neoral®
  • Nizoral®
  • Oxycontin®
  • Paxil®
  • Plavix®
  • Pravachol®
  • Prepulsid®
  • Prozac®
  • Rocephin®
  • Sandimmune®
  • Serzone®
  • Strattera®
  • Tarceva®
  • Targin®
  • Taxotere®
  • Tequin®
  • TobiPodhaler®
  • Tolectin®
  • Tracleer®
  • Trifexis®
  • Urso®
  • Valcyte®
  • Vancocin®
  • Vesicare®
  • Xeloda®
  • Zithromax®
  • Zometa®
  • Zoloft®
  • Zyprexa®